Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0WLEYA
ADC Name
LMB-100
Synonyms
LMB 100; huSS1-Fab-LO10R456A
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Colorectal cancer [ICD11:2B91]
Investigative
Antibody Name
Anti-MSLN scFv
  Antibody Info 
Antigen Name
Mesothelin (MSLN)
  Antigen Info 
Payload Name
Pseudomonas exotoxin LO10R456A
  Payload Info 
Therapeutic Target
Eukaryotic elongation factor 2 (EEF2)
  Target Info 
Linker Name
Undisclosed
TTD ID
D07RDQ
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 71.43
%
SW48 cells
Colon adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 81.6
%
SW48 cells
Colon adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 86.3
%
SW48 cells
Colon adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 88.7
%
SW48 cells
Colon adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 92.28
%
SW48 cells
Colon adenocarcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.55
ng/mL
KLM-1 cells
Pancreatic ductal adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 71.43% (Day 6) Positive MSLN expression (MSLN +++/++)
Method Description
In vivo efficacy of LMB-100 and LMB-164 in an SW48 mouse xenograft model was evaluated. LMB-100 was administered i.v. at 2.5 mg/kg dose every other day for 6 days for two cycles with three days in between cycles.
In Vivo Model SW48 CDX model
In Vitro Model Colon adenocarcinoma SW48 cells CVCL_1724
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 81.60% (Day 15) Positive MSLN expression (MSLN +++/++)
Method Description
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg).
In Vivo Model SW48 CDX model
In Vitro Model Colon adenocarcinoma SW48 cells CVCL_1724
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 86.30% (Day 9) Positive MSLN expression (MSLN +++/++)
Method Description
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg).
In Vivo Model SW48 CDX model
In Vitro Model Colon adenocarcinoma SW48 cells CVCL_1724
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 88.70% (Day 9) Positive MSLN expression (MSLN +++/++)
Method Description
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg) in combination with Oxaliplatin.
In Vivo Model SW48 CDX model
In Vitro Model Colon adenocarcinoma SW48 cells CVCL_1724
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 92.28% (Day 15) Positive MSLN expression (MSLN +++/++)
Method Description
Female nude mice were inoculated subcutaneously with SW48 cells in the right flank and underwent treatment beginning 10 days post inoculation. The model was treated with LMB-100 (2.5 mg/kg) in combination with Actinomycin D (0.3 mg/kg).
In Vivo Model SW48 CDX model
In Vitro Model Colon adenocarcinoma SW48 cells CVCL_1724
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.55 ng/mL±0.06 ng/mL Positive MSLN expression (MSLN +++/++)
Method Description
KLM-1 pancreatic adenocarcinoma cells were treated with indicated concentrations of LMB-12, LMB-100, or LMB-164 anti-MSLN targeted RITs for 72 hours before WST-8 assay of cell viability.
In Vitro Model Pancreatic ductal adenocarcinoma KLM-1 cells CVCL_5146
References
Ref 1 Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clin Colorectal Cancer. 2019 Sep;18(3):192-199.e1. doi: 10.1016/j.clcc.2019.06.006. Epub 2019 Jul 2.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.